Fluoxetine (sold as Prozac) has the strongest evidence base of any antidepressant for a 15-year-old and is one of only two antidepressants the FDA has approved for adolescent depression. The other is escitalopram (Lexapro), approved for ages 12 and up. That said, “best” depends on the individual teenager, and most guidelines recommend that medication work alongside therapy rather than replace it. The research behind these recommendations, and the practical questions parents and teens tend to have, is worth understanding in some detail.
What the FDA Has Approved for Adolescent Depression
Only two antidepressants carry FDA approval for major depressive disorder in the pediatric age range. Fluoxetine is approved for patients aged 8 to 17, and escitalopram is approved for patients aged 12 to 17.1Europe PMC / PubMed Central. Antidepressants for Pediatric Patients Other medications, including sertraline and citalopram, are frequently prescribed off-label based on clinical trial data, but they do not have the same regulatory stamp for this age group. For a 15-year-old, both approved options are on the table, and the choice between them usually comes down to how well the teen tolerates a given drug and any co-occurring conditions.
The distinction between “approved” and “off-label” matters less than you might think in day-to-day practice. Prescribers routinely use medications off-label when the evidence supports it and the approved options have not worked. Still, the fact that fluoxetine and escitalopram cleared the FDA’s bar means there is a larger body of controlled trial data behind them than behind most alternatives.
Why Fluoxetine Leads the Pack
Fluoxetine consistently comes out on top in large reviews of antidepressant trials in young people. A review of 71 separate trials found that fluoxetine appeared to be the most effective option, either alone or combined with cognitive behavioral therapy (CBT), and fewer patients stopped taking it compared with several other drugs, which suggests it is also more tolerable.2NIHR Evidence. Prozac may be the best treatment for young people with depression – but more research is needed A more recent network meta-analysis of 15 randomized controlled trials involving over 12,000 participants confirmed that fluoxetine was significantly better than placebo at improving scores on a standard depression rating scale used in pediatric trials.3PubMed Central. Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review
Most of fluoxetine’s clinical benefit appears within the first two weeks of treatment. If a teenager has shown no response by about four weeks, clinicians generally consider reevaluating the approach, whether that means adjusting the dose or trying a different medication.4PubMed Central. Time-to-effect of fluoxetine in children with depression This is a useful benchmark for families who are anxiously watching and wondering when to expect improvement.
There is a wrinkle worth mentioning. A 2021 Cochrane review raised questions about whether fluoxetine’s estimated benefit had shrunk over time as more trials accumulated, leading some researchers to argue the effect was no longer “clinically meaningful.”5Journal of Clinical Epidemiology. Has the estimated efficacy of fluoxetine for pediatric depression declined over time? Most treatment guidelines have not changed their first-line recommendation in response, and fluoxetine’s edge over other medications remains intact in head-to-head comparisons. But the debate underscores a broader truth about antidepressant research in young people: effect sizes are modest, and no medication is a silver bullet.
Escitalopram as the Second Approved Option
Escitalopram has its own respectable evidence base for adolescents. In a randomized, double-blind trial, adolescents on escitalopram showed significantly greater improvement on a standard depression scale than those on placebo, with a remission rate of about 51% compared with roughly 36% for placebo.6PubMed Central. Escitalopram in the Treatment of Adolescent Depression: A Randomized, Double-Blind, Placebo-Controlled Extension Trial The network meta-analysis mentioned earlier also found escitalopram scored highest among the drugs studied on measures of global functioning and clinical improvement.7PubMed Central. Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review
A systematic review and meta-analysis looking specifically at escitalopram in children and adolescents found its improvements over placebo were small and borderline statistically significant on depression rating scales, with roughly 11 patients needing to be treated for one additional patient to respond.8PubMed Central. Efficacy and Safety of Escitalopram for Major Depressive Disorder in Children and Adolescents: A Systematic Review and Meta-Analysis with Age-Specific Findings That “number needed to treat” figure might sound discouraging, but it is broadly in line with how antidepressants perform across all ages. The point is that escitalopram works, just not dramatically, and the same can be said for every antidepressant tested in teenagers.
Prescribers sometimes favor escitalopram over fluoxetine for practical reasons. Fluoxetine has an unusually long half-life and interacts with more medications through liver enzymes, which can matter if a teen is taking other drugs. Escitalopram tends to cause fewer drug interactions. The common side effects of escitalopram in trials included headache, nausea, insomnia, and stomach issues, most of which were mild to moderate.9PubMed Central. Escitalopram in the Treatment of Adolescent Depression: A Randomized, Double-Blind, Placebo-Controlled Extension Trial
Off-Label Options Like Sertraline
Sertraline (Zoloft) is one of the most commonly prescribed antidepressants for teenagers, despite not having formal FDA approval for pediatric depression. It is approved for obsessive-compulsive disorder in children, which has made clinicians comfortable with its safety profile in young people. Open-label studies in adolescents with depression have shown clinically meaningful improvements, with response rates reaching about 77% over 12 weeks in one small trial.10PubMed. Sertraline effects in adolescent major depression and dysthymia: a six-month open trial Longer-term data suggest the drug is well tolerated and safe over 24 weeks of treatment in children and adolescents.11PubMed. Long-term sertraline treatment of children and adolescents with major depressive disorder
The network meta-analysis found sertraline significantly better than placebo on depression rating scales and ranked it as the top performer on a measure of clinical severity.12PubMed Central. Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review The evidence is not as deep or as cleanly controlled as what exists for fluoxetine, but it is strong enough that many clinicians reach for sertraline as a reasonable alternative, especially if a family member has responded well to it (family history of drug response is one of the informal factors clinicians consider).
Why Medication Combined With Therapy Usually Wins
The landmark Treatment for Adolescents with Depression Study (TADS) randomized teens to four groups: fluoxetine plus CBT, fluoxetine alone, CBT alone, or placebo. The combination group had a response rate of about 71%, compared with roughly 61% for fluoxetine alone, 43% for CBT alone, and 35% for placebo.13JAMA. Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial Those numbers are cited in virtually every guideline on adolescent depression. A review of large trials concluded that the combination of an SSRI with CBT is superior for adolescents with moderately severe depression and for those who had not improved on medication alone.14PubMed Central. Combined Cognitive-Behavioral Therapy and Pharmacotherapy for Adolescent Depression: Does it Improve Outcomes Compared with Monotherapy?
Interestingly, a similar trial using sertraline instead of fluoxetine did not find that adding CBT to the medication was better than either treatment alone.15PubMed. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression The reasons are debated and may have to do with differences in study design or the specific CBT protocol used. The general clinical consensus still favors combination treatment, but these results are a reminder that one study’s finding does not always replicate neatly across different medications and settings.
For a 15-year-old starting treatment, the practical takeaway is that medication alone is rarely the whole plan. Most guidelines recommend starting with therapy for mild depression, and adding medication for moderate to severe cases. When medication is used, pairing it with a structured therapy gives the best odds of a good outcome.
The Black Box Warning on Suicidality
In 2004, the FDA added a black box warning to all antidepressants stating they may increase the risk of suicidal thoughts and behaviors in children and adolescents. The warning was based on placebo-controlled trials showing a higher rate of suicidality-related adverse events among young people taking antidepressants compared with placebo.16PubMed Central. Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified This remains a genuine finding: the clinical trials did show an increased risk of suicidal ideation in the medication groups.17PubMed. Intended And Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review
The warning has been controversial ever since. Some researchers argue it did more harm than good by scaring families away from medications that could help, contributing to a decline in antidepressant prescriptions and, paradoxically, an increase in suicide rates among young people in the years that followed.18PubMed Central. The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? Others maintain the warning is empirically justified and that close monitoring rather than avoidance of medication is the right response.
What this means for a 15-year-old starting an antidepressant: the risk is real but small, and it is manageable with proper monitoring. Most guidelines recommend weekly check-ins during the first month of treatment, then every other week for the next month, then monthly. Parents and teens should know the warning signs: new or worsening agitation, irritability, talk of self-harm, sudden changes in behavior. The risk is highest in the first few weeks after starting a medication or changing a dose. Depression itself carries a far higher risk of suicidality than the medication does, so avoiding treatment out of fear of the black box warning is generally a worse bet than starting treatment with good follow-up.
Side Effects and the Activation Problem
Beyond the suicidality concern, the most common side effects of SSRIs in adolescents are gastrointestinal symptoms (nausea, diarrhea, stomach pain), headaches, trouble sleeping, and sometimes changes in appetite or weight. Most of these are mild and tend to fade within the first couple of weeks.
A less well-known side effect is something clinicians call “activation.” This is a cluster of symptoms involving restlessness, impulsivity, and insomnia that was first identified as an SSRI side effect in the early 1990s but remains poorly characterized in terms of how common it actually is.19PubMed Central. Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management Activation can look alarming because a teenager who was withdrawn and low-energy may suddenly become agitated or unable to sit still. It does not necessarily mean the medication is wrong for them, but it does need clinical attention. In some cases, reducing the dose resolves it; in others, a switch to a different SSRI is the right call.
A review of the evidence on SSRI safety and the developing adolescent brain found little evidence that the adolescent brain is at developmental risk from SSRIs, and concluded that the clinical benefits outweigh the risks for moderate to severe depression.20Sage Journals / Journal of Psychopharmacology. Antidepressants and the adolescent brain That finding is reassuring for parents who worry about their teenager taking a brain-altering medication during a period of rapid neural development.
Medications That Do Not Work Well for Teens
Not every antidepressant that works in adults works in adolescents. Two classes in particular have disappointing track records. Tricyclic antidepressants, an older class that includes drugs like imipramine and nortriptyline, showed no meaningful benefit over placebo in children and only marginal evidence of benefit in adolescents across a Cochrane review of multiple trials.21PubMed Central. Tricyclic drugs for depression in children and adolescents On top of the lack of benefit, tricyclics caused significantly more side effects, including dizziness, drops in blood pressure upon standing, tremor, and dry mouth. An earlier meta-analysis reached the same conclusion, finding no significant benefit of treatment.22BMJ. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis
Venlafaxine (Effexor), a serotonin-norepinephrine reuptake inhibitor sometimes used in adults, has also fared poorly in adolescent depression trials, showing only minimal improvement in depressive symptoms in adolescents and no improvement in children. It also carried a higher rate of suicidal ideation compared to placebo in depression trials, roughly double the risk difference seen with other drugs.23Pediatric Health. Venlafaxine extended release in pediatric anxiety and depression There is one exception: when a teenager has not responded to two SSRIs and is being switched as part of a treatment-resistant protocol, venlafaxine may be tried, but only with careful monitoring.
When the First Medication Does Not Work
Roughly a third of adolescents do not respond adequately to their first SSRI trial. A large randomized trial studied what to do next by assigning these non-responders to either a different SSRI, a different SSRI plus CBT, venlafaxine alone, or venlafaxine plus CBT. The most consistent finding was that adding CBT to the medication switch improved response rates more than switching medication alone.24PubMed Central. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response The combination advantage was especially pronounced for teens who had other conditions alongside depression, such as anxiety or ADHD. Having fewer comorbid conditions and less severe depression at baseline also predicted better outcomes regardless of treatment arm.
Doses should generally be increased as rapidly as the teen can tolerate, preferably every one to two weeks, until remission is achieved or side effects become a problem.25Europe PMC. Achieving adolescent adherence to treatment of major depression. A common mistake is leaving a teenager on a low starting dose for months without adjusting. If there is no meaningful improvement after four to six weeks at an adequate dose, that is not the medication slowly working; it is the medication not working at that dose or at all.
Pharmacogenetic Testing
You may have heard about genetic tests that claim to predict which antidepressant will work best for a specific person. These tests look at genes involved in drug metabolism, primarily the cytochrome P450 enzyme family, and can identify whether someone processes a given medication unusually fast or unusually slowly. The idea is appealing: skip the trial and error, go straight to the right drug.26PubMed Central. Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
In practice, the evidence for pharmacogenetic testing in adolescent depression is still emerging. The tests are good at identifying who will metabolize a drug unusually, which can help avoid side effects or therapeutic failure at standard doses. But they cannot reliably predict which medication will produce the best antidepressant response, because drug metabolism is only one piece of a much more complex puzzle. Some clinicians order these tests after a first medication fails, using the results to guide the next choice. Others consider them premature. Insurance coverage is inconsistent, and the cost without coverage can be substantial.
The Placebo Problem in Teen Depression Research
One reason it has been so hard to prove that antidepressants work in teenagers is an unusually high placebo response rate in pediatric depression trials.27PubMed. The Impact of Placebo Response Rates on Clinical Trial Outcome: A Systematic Review and Meta-Analysis of Antidepressants in Children and Adolescents with Major Depressive Disorder In many studies, a large proportion of teens on placebo improve, which makes the gap between drug and placebo look small even if the drug is genuinely helping. This does not mean antidepressants are ineffective; it means the statistical bar for proving they work in a clinical trial is unusually high for this age group. Part of the explanation may be that participating in a study itself provides structure, attention, and hope that a depressed teenager has been lacking.
This high placebo rate also helps explain why so many antidepressants have “failed” in pediatric trials. A drug that works well may still fail to separate from placebo if the placebo group improves dramatically. Clinicians who treat depressed teens every day often report seeing clearer benefits in practice than the trials suggest, and the high placebo response is likely a big part of the explanation for that disconnect.
Stopping an Antidepressant Safely
Eventually, many teenagers and their families want to know when and how to stop the medication. Withdrawal symptoms are a real consideration and vary by drug. They can include irritability, anxiety, nausea, headaches, insomnia, dizziness, and unusual sensations sometimes described as “brain zaps.” These symptoms relate to how quickly the drug leaves the body and how the brain readjusts.28PubMed Central. Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms
Fluoxetine, with its long half-life, tends to cause fewer withdrawal symptoms than shorter-acting SSRIs like paroxetine or sertraline, because it essentially tapers itself out of the body more gradually. Regardless of which medication a teen is on, stopping abruptly is a bad idea. A gradual taper over weeks or months, guided by a clinician, is standard practice. Most guidelines also recommend continuing the antidepressant for at least six to twelve months after symptoms have fully resolved before considering a taper, since stopping too early significantly increases the risk of relapse.
When Depression Comes With Other Conditions
Depression in teenagers rarely shows up alone. Anxiety disorders, ADHD, and substance use are common companions, and the mix affects which medication makes the most sense. SSRIs are effective for both depression and most anxiety disorders, which makes them a natural first choice when both conditions are present. When ADHD coexists with depression, some SSRIs can be used alongside stimulant medications, though the combination requires careful monitoring.29Europe PMC. Major Depression with ADHD: In Children and Adolescents.
For teens with treatment-resistant depression and multiple comorbid conditions, the evidence from switching studies suggests that adding CBT to a medication change produces the strongest benefit precisely in those more complex cases.30PubMed Central. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response In other words, the teens who seem hardest to treat are the ones who benefit most from a combination approach. That is genuinely encouraging, even if the overall effect sizes across all these treatments remain smaller than most families would hope for.